NeoPharm to Investigate Treatment for Deadly Lung Disease
The drug candidate IL13-PE has the potential to be the first effective therapy for idiopathic pulmonary fibrosis (IPF), which kills an estimated 40,000 people in the United States each year.
News
Implantable Weight-Loss Device Receives CE Mark Approval
GI Dynamics has received European CE mark approval to commercialize a non-surgical device for the management of obesity and Type 2 diabetes.
Resverlogix to Begin Phase II Atherosclerosis Trial
Canadian biopharmaceutical company Resverlogix has commenced a Phase II clinical trial for RVX-208, its small molecule therapy for the treatment of atherosclerosis in patients with stable coronary artery disease.
Researchers Identify Gene Linked to Childhood Asthma
U.S. researchers have identified a gene that is linked to childhood asthma.
Clarient Acquires AGI In All-Stock Merger
Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
New Era Begins for NeoStem Following China Acquisition
NeoStem is an innovator and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications.
Ambit and Astellas Sign $350M Development Deal
The deal will include Ambit’s AC220, a kinase inhibitor currently in Phase II trials to treat a form of blood cancer called acute relapsed/refractory myeloid leukemia (AML).
Possible Cause of Inflammatory Bowel Disease Uncovered
A researcher at the University of Adelaide found that people suffering from inflammatory bowel disease have a lower number of regulatory cells that control the immune system.
Cubist/Calixa Deal the Latest in a String of Biotech Buyouts
Cubist Pharmaceuticals has announced plans to acquire tiny San Diego biotech Calixa Therapeutics for up to $402.5 million.